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Clostridium difficile is an opportunistic pathogen inhabiting the human gut, often being
the aetiological agent of infections after a microbiota dysbiosis following, for example,
an antibiotic treatment. C. difficile infections (CDI) constitute a growing health problem
with increasing rates of morbidity and mortality at groups of risk, such as elderly and
hospitalized patients, but also in populations traditionally considered low-risk. This could
be related to the occurrence of virulent strains which, among other factors, have high-
level of resistance to fluoroquinolones, more efficient sporulation and markedly high
toxin production. Several novel intervention strategies against CDI are currently under
study, such as the use of probiotics to counteract the growth and/or toxigenic activity
of C. difficile. In this work, we have analyzed the capability of twenty Bifidobacterium
and Lactobacillus strains, from human intestinal origin, to counteract the toxic effect
of C. difficile LMG21717 upon the human intestinal epithelial cell line HT29. For this
purpose, we incubated the bacteria together with toxigenic supernatants obtained from
C. difficile. After this co-incubation new supernatants were collected in order to quantify
the remnant A and B toxins, as well as to determine their residual toxic effect upon HT29
monolayers. To this end, the real time cell analyser (RTCA) model, recently developed
in our group to monitor C. difficile toxic effect, was used. Results obtained showed that
strains of Bifidobacterium longum and B. breve were able to reduce the toxic effect of the
pathogen upon HT29, the RTCA normalized cell-index values being inversely correlated
with the amount of remnant toxin in the supernatant. The strain B. longum IPLA20022
showed the highest ability to counteract the cytotoxic effect of C. difficile acting directly
against the toxin, also having the highest capability for removing the toxins from the
clostridial toxigenic supernatant. Image analysis showed that this strain prevents HT29
cell rounding; this was achieved by preserving the F-actin microstructure and tight-
junctions between adjacent cells, thus keeping the typical epithelium-like morphology.
Besides, preliminary evidence showed that the viability of B. longum IPLA20022 is
needed to exert the protective effect and that secreted factors seems to have anti-toxin
activity.
Keywords: probiotics, Clostridium difficile, toxins, RTCA, xCelligence, Bifidobacterium, Lactobacillus,
microscopy
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INTRODUCTION
Clostridium difficile is a Gram-positive, spore-forming, motile
and strict anaerobe rod that can be found in the gastrointestinal
tract of humans and animals (Janezic et al., 2014). The current
classification of the “Bergey’s Manual of Systematic Bacteriology”
includes C. difficile in the Phylum Firmicutes, Class Clostridia,
Order Clostridiales and Family Peptostreptococcaceae (Ludwig
et al., 2009). A recent taxonomic study, based on 16S rRNA
and ribosomal protein sequences, ascertains that C. difficile
belongs to this family and proposes that it should be renamed
as Peptoclostridium difficile (Yutin and Galperin, 2013); this new
name appears in the taxonomic classification and nomenclature
catalog of NCBI1, but still C. difficile remains as the name
recognized by the clinical and scientific community.
C. difficile infection (CDI) is the main cause of diarrhea
associated with antibiotic use or related to health-care
environments (Leﬄer and Lamont, 2015) and increasing
incidence is reported among populations previously considered
as low risk, such as pregnant women and children (Carter
et al., 2012). The ubiquity of this bacterium, in combination
with its capability to form spores, makes hospital environments
a good source for C. difficile acquisition, although zoonotic
(Bauer and Kuijper, 2015) and food transmissions (Troiano
et al., 2015) have been proposed as well. The incidence and
severity of CDI has been growing since the beginning of this
century due to the global occurrence of hypervirulent strains
such as BI/NAP1/027 (group BI by restriction endonuclease
analysis, North American pulse-field type NAP1 by pulse-field
gel electrophoresis, and ribotype 027; Rupnik et al., 2009; Yakob
et al., 2015). The antibiotics metronidazole and vancomycin
are the current treatments for CDI, but this does not prevent
the high rates of recurrence. Thus, new emerging therapeutic
options, such as fecal microbiota transplantation (FMT), new
antibiotics, bacteriocins, bacteriophages, and probiotics are
under evaluation for the control of CDI (Martin et al., 2013;
Dunne et al., 2014; Mathur et al., 2015). Indeed probiotics,
which are “live microorganisms that, when administered
in adequate amounts, confer a health benefit on the host”
(FAO-WHO, 2001; Hill et al., 2014), have been proposed as
biotherapeutic agents to help microbiota restoration after
a dysbiosis caused by antibiotics or infections (Reid et al.,
2011).
The information encoded on the genomes of this species,
excellently reviewed by Knight et al. (2015), reveals high
plasticity and very low levels of conservation among strains.
This genetic diversity is reflected in its physiological adaptation
to different ecosystems and in the occurrence of different
phenotypes. In addition, the presence of a wide variety of
transposons and phages explain the lineage evolution of clinically
relevant loci, such as the antimicrobial resistance genes and
the PaLoc (pathogenicity locus), among others (Knight et al.,
2015). The PaLoc harbors, together with three additional genes,
tcdA and tcdB coding for toxin A and toxin B, respectively,
which are the major C. difficile virulence factors (Monot
1http://www.ncbi.nlm.nih.gov/taxonomy/?term=Peptoclostridium%20difficile
et al., 2015). The modulating environmental signals regulating
the expression of PaLoc is not totally understood and a
recent report shows that toxin synthesis is regulated through
quorum-sensing signaling (Darkoh et al., 2015). TcdA and
TcdB are large toxins whose main mechanism of action is
known, although host receptors and toxin-mediated responses
still remain to be fully deciphered. They act as intracellular
glycosyltransferases modifying the Ras superfamily of small
GTPases thus inducing intracellular changes, including F-actin
condensation, transcriptional activation and cell apoptosis
of intestinal epithelial cells. This promotes the disruption
of the tight junctions and barrier integrity, leading to an
increase in the gut permeability and neutrophil infiltration.
Downstream effects also include modifications in the chemokine
and cytokine production patterns toward an inflammatory
response and fluid accumulation, ending with the clinical
manifestations of leukocytosis and diarrhea (Voth and Ballard,
2005; D’Auria et al., 2013; Carter et al., 2015; Leslie et al.,
2015). Therefore, anti-toxin therapies to counteract the negative
effects of these potent C. difficile virulence factors could be
valuable tools to reduce the course of CDI (Tam et al.,
2015).
In a previous study we developed a biological model, using the
(human) intestinal epithelial cell line HT29, to follow in real time
the effect of supernatants collected from C. difficile cultures of a
TcdA+, TcdB+ (toxinotype 0) strain. This method is based on
the continuous monitoring of the impedance signal, transmitted
through gold microelectrodes placed in the bottom of microtiter
plates, of HT29 monolayers (Valdés et al., 2015). Our aim in
the present work is to search for lactobacilli and bifidobacteria
probiotic candidates with anti-toxin capability able to protect
HT29 cells from the cytotoxicity caused by toxigenic C. difficile
supernatants.
MATERIALS AND METHODS
Bacterial Strains and Culture Conditions
The Bifidobacterium and Lactobacillus species used in this
study are listed in Table 1. Most strains belonging to IPLA
culture collection were isolated from infant feces and breast
milk (Solís et al., 2010), whereas IPLA20031 and IPLA20032
were obtained after adaptation to increasing concentrations of
bile salts from a parental strain isolated from a dairy product
(Ruas-Madiedo et al., 2010). Strains were grown in MRSC
[MRS (Biokar Diagnostics, Beauvois, France) supplemented
with 0.25% L-cysteine (Sigma-Chemical Co., St. Louis, MO,
USA)] at 37◦C in the anaerobic chamber MG500 (Don Whitley
Scientific, Yorkshire, UK) under 80% N2, 10% CO2 and 10%
H2 atmosphere. As standard procedure bacterial stocks, kept
at −80◦C in MRSC + 20% glycerol, were spread onto the
surface of agar-MRSC and incubated for 3 days. A single
colony was picked to inoculate MRSC broth which, after
24 h incubation, was used to inoculate (2%) 10 ml fresh
MRSC broth. This culture was incubated overnight (18 h)
to prepare the bacterial suspensions that will be described
next.
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TABLE 1 | Strains included in this study and normalized cell index (CI) obtained at 4 and 22 h after addition of neutralized cell-free supernatants (NCFS)
collected from incubations of each bifidobacteria or lactobacilli strain with 2.5% of toxigenic Clostridium difficile LGM21717 supernatant (Tox-S).
Mean ± SD
Normalized-CI Remnant toxin (ng/ml)
NCFS Strain After 4 h After 22 h TcdA TcdB
C. difficile Tox-S (2.5%) LMG21717∗ −0.64 ± 0.13 −0.93 ± 0.11 4.41 ± 0.01 0.48 ± 0.0
B. bifidum LMG13195∗ −0.62 ± 0.13 −0.97 ± 0.10 4.05 ± 0.33 0.15 ± 0.01
IPLA20024 −0.43 ± 0.12 −0.92 ± 0.10 2.87 ± 0.02 0.11 ± 0.01
IPLA20025 −0.64 ± 0.08 −1.03 ± 0.07 3.47 ± 0.09 0.14 ± 0.02
IPLA20017 −0.71 ± 0.11 −1.04 ± 0.07 3.50 ± 0.12 0.42 ± 0.01
B. animalis DSM15954† (Bb12) −0.58 ± 0.09 −1.00 ± 0.13 3.71 ± 0.33 0.41 ± 0.04
IPLA20031 (A1dOx) −0.53 ± 0.05 −1.04 ± 0.07 4.60 ± 0.48 0.58 ± 0.26
IPLA20032 (A1dOxR) −0.64 ± 0.11 −1.00 ± 0.12 4.32 ± 0.3 0.42 ± 0.03
IPLA20020 −0.62 ± 0.07 −1.05 ± 0.08 4.08 ± 0.42 0.42 ± 0.04
B. longum IPLA20021 −0.16 ± 0.11 −0.60 ± 0.20 1.50 ± 0.14 0.29 ± 0.14
IPLA20022 −0.06 ± 0.05 −0.06 ± 0.12 0.54 ± 0.18 0.26 ± 0.04
IPLA20001 −0.09 ± 0.06 −0.33 ± 0.19 1.71 ± 0.05 0.26 ± 0.04
IPLA20002 −0.07 ± 0.08 −0.57 ± 0.09 1.25 ± 0.16 0.22 ± 0.05
B. breve IPLA20004 −0.00 ± 0.04 −0.24 ± 0.12 0.75 ± 0.09 0.21 ± 0.08
IPLA20005 −0.03 ± 0.03 −0.25 ± 0.09 0.56 ± 0.29 0.15 ± 0.01
IPLA20006 −0.12 ± 0.01 −0.66 ± 0.08 1.05 ± 0.37 0.12 ± 0.01
B. pseudocatenulatum IPLA20026 −0.45 ± 0.06 −0.91 ± 0.13 3.31 ± 0.02 0.40 ± 0.12
L. crispatus IPLA20120 −0.44 ± 0.06 −0.91 ± 0.00 4.09 ± 1.64 0.22 ± 0.09
L. gasseri IPLA20121 −0.42 ± 0.04 −0.91 ± 0.03 3.68 ± 1.28 0.43 ± 0.16
L. paracasei IPLA20124 −0.39 ± 0.03 −0.83 ± 0.03 4.57 ± 0.26 0.46 ± 0.03
L. rhamnosus LMG18243∗ (GG) −0.41 ± 0.03 −0.83 ± 0.03 3.35 ± 0.44 0.42 ± 0.04
∗LMG: Belgian Coordinated Collections of Microorganisms” (BCCM, Gent, Belgium).
†DSM: German Collection of Microorganisms and Cell cultures (DSMZ, Braunschweig, Germany).
The remnant toxins in these NCFS were quantified by ELISA tests. Data were obtained from two biological replicates each measured by duplicate.
The strain C. difficile LMG21717 (∼ATCC9689, Ribotype
001, genes tcdA+, tcdB+, cdtB-) producing both TcdA and
TcdB toxins (Toxinotype 0) was purchased from the “Belgian
Coordinated Collections of Microorganisms” (BCCM, Gent,
Belgium). The strain was routinely grown in Reinforced
Clostridium Medium (RCM, Oxoid, Thermo Fisher Scientific
Inc., Waltham, MA, USA) in Hungate tubes under anaerobic
conditions at 37◦C. Frozen stocks (−80◦C in RCM + 20%
glycerol) were directly activated in RCM broth incubated for 24 h
and this culture was used to inoculate (2%) fresh medium that was
cultivated for 13 h. This culture was used as inoculum to obtain
the toxigenic supernatant.
Preparation of Toxigenic C. difficile Supernatant
Conditions to obtain toxigenic supernatant from C. difficile
LMG21717 have previously been determined and published
(Valdés et al., 2015). In short, 300 µl of RCM grown culture
were used to inject into Hungates tubes containing 15 ml of
Gifu Anaerobic Medium (GAM, Nissui Pharmaceutical Co., Ltd.,
Tokyo, Japan). GAM cultures were incubated for 48 h and
centrifuged (16,000 × g, 10 min) to obtain the C. difficile-free
toxigenic supernatant (Tox-S), which was kept in several aliquots
at−80◦C.
Two independent ELISA tests (tgcBIOMICS GmbH, Bingen,
Germany) were used to quantify the concentration of TcdA
or TcdB in the toxigenic supernatant, as well as the remnant
toxins in the neutralized bacterial-supernatants obtained after
incubation of Tox-S with bifidobacteria and lactobacilli.
Incubation of Bifidobacteria or Lactobacilli with
Toxigenic C. difficile Supernatant
The experimental design carried out in this study is schematized
in Supplementary Figure S1A. Bifidobacteria and lactobacilli
cultures grown for 18 h in MRSC were washed twice with
PBS and resuspended at 109 cfu/ml in the HT29-cultivation
medium (MM, described below) supplemented with 5% of
Tox-S from C. difficile or without supplementation (controls).
After incubation for 1 h under anaerobic conditions and mild
stirring (∼300 rpm), the bacterial suspensions were centrifuged
(16,000 × g, 10 min) to obtain bifidobacteria- or lactobacilli-free
bacterial supernatants. Then, the pH was increased to 7.55± 0.05
with 1 and 0.1 N NaOH and the volume obtained was adjusted
to twice the initial one with MM; this means that the maximum
amount of remnant toxin that could be present was 2.5%. These
neutralized cell-free supernatants (NCFS) were directly used to
test their cytotoxicity upon HT29 monolayers as well as to
quantify the remnant TcdA and TcdB toxins. This screening
was performed with two biological replicates, each analyzed in
duplicate, of each bacterial strain using HT29 monolayers of two
consecutive passages (p147 and p148).
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Incubation of Dead and Live B. longum IPLA20022
with Toxigenic C. difficile Supernatant
The strain B. longum IPLA20022 was selected in order to
determine whether the capability to diminish the cytotoxic
effect of C. difficile supernatant was dependent on bacterial
viability. For that purpose UV-treated IPLA20022 suspensions
were prepared from MRSC-grown cultures that were washed and
resuspended in PBS at 109 cfu/ml. Then, the PBS suspension
was poured into several petri dishes allowing a high surface
spread and they were submitted to ultra violet radiation in a UV-
chamber (15W, Selecta, Barcelona, Spain). Three UV cycles of
30 min were applied, homogenizing the PBS suspension in each
interval, and the absence of viability was checked by plating serial
dilutions of UV-treated IPLA20022 suspension in agar-MRSC
(López et al., 2012). Incubation of this UV-treated suspension
(dead IPLA20022) with toxigenic C. difficile supernatant was
performed as previously described. A non UV-killed suspension
(live IPLA20022) of the same culture was used as control. After
incubation for 1 h, both suspensions were processed to obtain the
respective NCFS (Supplementary Figure S1A). This experiment
was carried out with three independent cultures (biological
replicates) of strain IPLA20022 upon HT29 monolayers within
the same passage (p149), each measured in duplicate.
Incubation of Supernatants from B. longum
IPLA20022 with Toxigenic C. difficile Supernatant
To test the activity of putative secreted factors by B. longum
IPLA20022 against C. difficile toxins, cell-free bifidobacterial
supernatants obtained from three independent-culture replicates
(each analyzed in duplicate) were incubated with 50% toxigenic
(Tox-S) supernatant for 1 h under anaerobic conditions.
Afterward, supernatants were neutralized (pH ≥ 7.5) and its
cytotoxic activity tested upon HT29 monolayers (passage p149)
at 2.5% in MM (Supplementary Figure S1B).
Intestinal Epithelial Cell Line HT29 and
Culture Conditions
The intestinal cell line HT29 (ECACC 91072201), from human
colon adenocarcinoma, was purchased from the “European
Collection of Cell Cultures” (Salisbury, UK) and stored at
IPLA under liquid N2. McCoy’s Medium (MM) supplemented
with 10% foetal bovine serum (FBS), 3 mM L-glutamine and
a mixture of antibiotics (50 µg/ml streptomycin-penicillin,
50 µg/ml gentamicin and 1.25 µg/ml amphotericin B) was used
for HT29 cultivation. The pH value of supplemented MM was
7.48± 0.02. All media and reagents were purchased from Sigma–
Aldrich. Maintenance of the cell line, between passages 145 to
149, was performed under standard conditions, at 37◦C 5%
CO2 atmosphere, in a CO2-Series Shel-Lab incubator (Sheldon
Manufacturing Inc., OR, USA).
Monitoring Behavior of HT29 in RTCA
The real time cell analyzer (RTCA-DP) xCelligence (ACEA
Bioscience Inc., San Diego, CA, USA) used to monitor HT29
cells performance upon the different conditions tested, was
introduced in a Heracell-240 Incubator (Thermo Electron LDD
GmbH, Langenselbold, Germany) set at 37◦C with 5% CO2
atmosphere. This technology records variations in impedance
due to the adhesion, growth and morphological changes of HT29
cells during interaction with gold-microelectrodes placed in the
bottom of specific microtiter plates (E-plates). The impedance
signal is converted in the arbitrary “cell index” (CI) unit which is
recorded in the external computer allowing, as well, data analyses
through the RTCA software 1.2.1 (ACEA Bioscience).
The method to monitor the damage caused by C. difficile
toxins was previously described by Valdés et al. (2015). In short,
16-well E-plates were seeded with 2× 105 HT29 cells (in 100 µl)
and monitored (recording signal every 15 min) for 22 h to ensure
the formation of a monolayer (confluent state). Afterward, the
medium was removed and 200 µl of the different bacterial NCFS
were added per well. Additionally, wells containing 200 µl of
a control without bacteria but with Tox-S (added at 2.5% in
MM, cytotoxic control) or 200 µl MM medium without bacteria
or Tox-S added (non-cytotoxic control) were included in each
experiment. The monitoring continued (every 10 min) for an
additional 20–22 h under standard incubation conditions. CI
values recorded were normalized by the time of the supernatant
addition and by the control sample (MM) as previously described
(Valdés et al., 2015). Samples of each bacterial supernatant were
obtained from, at least, duplicated biological experiments (two
independent Tox-S vs. bifidobacteria or lactobacilli incubations)
and each NCFS was tested in duplicate (two independent wells
within the same E-plate). Thus, four normalized-CI data were
obtained per each bacterial strain tested.
Image Analysis of HT29 Behavior
Time-Lapsed Monitoring in Real Time
Several images were captured in real time using the compact,
inverted, optical microscope (40× objective) LumaScope-600
Series (Etaluma, Carlsbad, CA, USA) which was placed inside
the Heracell-240 incubator. Images were recordered in an
external computer with the software LumaView600Cy 13.7.17.0
(Etaluma). To this end, 2-well µ-Slide (ibiTreat, 1.5 polymer
coverslip, tissue culture treated, sterilized slides, Ibidi GmbH,
Martinsried, Germany) were seeded with 2 × 106 HT29 cells/ml
(1 ml) and placed on top of the microscope objective. Images
were recorded every 15 min until the confluent state was reached
(about 22 h); afterward, culture medium was removed and 1 ml
of fresh medium containing 2.5% Tox-S or 1 ml of the NCFS
collected after incubation of live B. longum IPLA20022 with Tox-
S, was added in two independent µ-Slides. Image capture was
performed for additional an 16 h.
End-Point CSLM Analysis
HT29 monolayers submitted to different treatments were
analyzed by confocal scanning laser microscopy (CSLM) after
an end-point incubation period of 20 h. For this, 8-well
µ-Slide (ibiTreat, Ibidi GmbH) were seeded with 2 × 106
HT29 cells/ml (0.3 ml) and incubated for 22 h to reach
confluent state. Afterward, supernatant was removed and wells
(in duplicate) were filled with the same volume of fresh medium
containing MM (control), 2.5% Tox-S, and NCFS from live or
dead B. longum IPLA20022 incubated with Tox-S. Incubation
continued for additional 20 h; then, supernatant of each well was
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removed and HT29 monolayers fixed with 1 vol (0.3 ml) of cold
(−20◦C) acetone for 10 min. Samples were washed twice with
PBS for 5 min under mild stirring and permeabilised with PBS
containing 0.1% Triton 100x (Sigma) for 15 min. The nonspecific
binding sites were blocked with FBS (25% in PBS) for 20 min and
finally washed once with PBS. The Phalloidin-Alexa-Fluor-568
probe (Molecular Probes-Thermo Fisher, Life Technologies S.A.,
Madrid, Spain) toward F-actin was added in 0.3 ml of PBS (final
concentration of 25µl/ml) and samples were incubated overnight
at 4◦C in darkness. After washing twice with PBS, HT29 nucleus
were stained with DAPI probe (Merck-Millipore Cor., Billerica,
MA, USA) used at 1:1000 (final dilution in PBS) and incubated
under the same conditions for, at least, 6 h. Finally, samples were
washed and added to 0.3 ml of PBS previous visualization under
microscope.
For the CSLM analysis the Leica TCS AOBS SP8 X confocal
microscopy (Leica Microsystems GmbH, Heidelberg, Germany)
located in the Scientific-Technical Services of Oviedo University,
was used. DAPI and Alexa-Fluor-568 fluorochromes were excited
at 405 nm by a blue–violet laser diode and at 578 nm by a
white light laser, respectively. Z-stacks of HT29 samples were
acquired using a 63x/1.4 oil objective applying a line average of
2 to reduce noise on the final images and a z-step of 1 micron.
Details of a region were later acquired using a 2.50 optical zoom.
Image-captures were recorded with the “Leica Application Suite
X” software version 1.8.1.13759 (Leica).
Statistical Analysis
To assess differences in the response (normalized CI) of HT29
due to the anti-toxin activity of B. longum IPLA20022, one-way
ANOVA followed by SNK (Student-Newman–Keuls, p < 0.05)
mean comparison tests were performed. The statistical package
IBM SPSS Statistics for Window Version 22.0 (IBM Corp.,
Armonk, NY, USA) was used to carry out these analyses. Legend
of Figure 4 describes the comparisons made in each type of
experiment.
RESULTS
The method previously developed by our group to detect in
real time the toxic effect of C. difficile upon intestinal cell lines
was used to address the anti-toxin probiotic potential of twenty
bifidobacteria and lactobacilli strains. As an initial step several
parameters were optimized in order to establish conditions
for the screening using as a biological model confluent-HT29
monolayers (data no shown). Finally, neutralized (pH ≥ 7.5)
cell-free supernatants (NCFS), obtained after incubation (1 h,
37◦C, anaerobiosis) of each strain (about 1 × 109 cfu/ml)
with 5% C. difficile supernatant (Tox-S), were used for this
study (Supplementary Figure S1A). The behavior of HT29
monolayers was monitored in real time recording the variations
in the impedance signal (normalized-CI) over time due to the
presence of the NCFS, the toxigenic control (2.5% Tox-S), or
the culture media alone (MM; Figure 1). To understand the
impedance graphs is worth noting that the lowest normalized-
CI value indicates the highest toxigenic capability of C. difficile
supernatant upon HT29; thus, in Figure 1, the red line
(representing values obtained with 2.5% Tox-S) is the control
for damage, whereas the pink line represents the non-toxigenic
control (MM) used as a reference for normalization of all
CI values being the reason to have “0 value.” Regarding the
effect of NCFS, those obtained after incubation of strains in
MM medium without C. difficile toxins (dotted lines) showed
normalized-CI values equal or higher to the control, therefore
indicating the absence of any toxic effect induced by the putative
probiotics. However, when the NCFS obtained from bacteria
incubated with Tox-S were analyzed, HT29 monolayers behaved
differently depending on the species considered (Figure 1).
Graphics obtained clearly show that strains belonging to species
Bifidobacterium bifidum and B. animalis subsp. lactis had no
protective effect against C. difficile toxins since the normalized-
CI lines obtained showed similar, or even lower, values than
the toxigenic Tox-S control. By contrast, the normalized-CI
obtained from the four lactobacilli tested, as well as the strains of
B. longum, B. breve, and B. pseudocatenulatum were higher than
those induced by C. difficile supernatant. In general, normalized-
CI lines from B. longum and B. breve strains were the closest
to the control, thus being the strains showing higher anti-toxin
capability.
Normalized-CI obtained 4 h after NCFS addition (short term
effect) or 22 h after (long term effect) were analyzed in more
detail (Table 1). Results obtained in the short term showed that
all strains belonging to B. longum and B. breve, as well as L. gasseri
IPLA20121, L. paracasei IPLA20124 and L. rhamnosus GG,
seemed to have higher values of normalized-CI than the toxigenic
control. However, none of the lactobacilli were able to keep
the protective effect upon HT29 for a prolonged period (22 h).
The strain C. difficile LMG21717 used in this study produced
about ten-times more TcdA than TcdB (Table 1) and the strains
showing high protective effect were those that apparently were
more effectively in reducing the concentration of TcdA, i.e.,
belonging to B. longum and B. breve species (Table 1). Indeed, the
NCFS obtained from strain B. longum IPLA20022 that promoted
the lowest damage after 22 h only had 12% of remnant TcdA. Of
note is that NCFS from B. bifidum and B. breve seemed to have
a good ability to reduce TcdB levels (remnant between 23 and
44%), although this fact was not correlated with higher protective
effect in B. bifidum because this species seemed to be less effective
against TcdA.
Time-lapsed microphotographs (Figure 2) showed that HT29
cells treated with 2.5% toxigenic C. difficile supernatant become
spherical and the integrity of the monolayer was lost when
incubation was prolonged (Figure 2A). However, monolayers
added with NCFS from live B. longum IPLA20022 incubated with
Tox-S remained more stable and only after a long incubation
period (16 h) some cellular particles were released to the culture
medium (Figure 2B). Furthermore, although the cytopathic
mechanism of C. difficile toxins is well known, we performed
immunohistochemistry CSLM analysis to confirm the cellular
events under different treatments (Figure 3). Control HT29
monolayers (grown in MM for 20 h) showed a typical F-actin
cytoskeleton in which the nucleus is imbibed, thus having an
epithelial-like morphology with annexed cells well connected.
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FIGURE 1 | Variation in the normalized cell index (Normalized-CI) of HT29 monolayers treated with different neutralized cell-free supernatants (NCFS;
neutralized cell-free supernatants) obtained in a representative experiment after incubation of toxigenic Clostridium difficile supernatant (Tox-S)
with different strains of Bifidobacterium and Lactobacillus species. The Tox-S was tested alone at 2.5% (red line). Normalization was performed with respect
to the point of NCFS’s addition and with respect to the control sample (culture medium MM without supernatant addition) which is the 0-reference control (pink line).
The dotted lines represent results obtained with the NCFS obtained after incubation of the same strains in MM (without Tox-S). Representative SD values of these
data are collected in Table 1.
However, monolayers treated for the same period with Tox-S
supernatant lost the interconnection among F-actin filaments
(Figure 3B) and the nucleus seems to be in the initial stages
of apoptosis, i.e., the chromatin initiates the condensation
showing more intense blue due to DAPI staining (Figure 3C and
Supplementary Figure S2); therefore, HT29 cells become more
spherical (non-epithelial morphology) and it seems that the tight
junctions that maintain the monolayer integrity might have been
disrupted (Figure 3A). The photographs obtained from HT29
monolayer treated for 20 h with the NCFS from live B. longum
IPLA20022 were more similar to the control without toxin; the
F-actin cytoskeleton still showed an interconnected structure and
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FIGURE 2 | Images of HT29 monolayers captured in real time (37◦C, 5% CO2) with the inverted optical microscope (objective 40×) at three incubation
times (0, 4, and 16 h). Monolayer treated with toxigenic C. difficile supernatant (Tox-S, A) or with NCFS (neutralized cell-free supernatants) obtained after incubation
of live Bifidobacterium longum IPLA20022 with Tox-S (B).
the nucleus showed less intense DAPI staining comparable to that
of the negative control than the toxigenic control. This structure,
resembling that of intact epithelial monolayers, is in agreement
with the presence of lower amounts of remnant toxin in the NCFS
and higher normalized-CI due to the capability of this strain to
counteract the effect of clostridial toxins.
In order to determine whether this strain retains its
anti-toxin capability under non-viable conditions, B. longum
IPLA20022 suspension was irradiated with UV light for 90 min.
The RTCA monitoring clearly showed that this treatment
modified the protective effect of the bifidobacteria upon
HT29 since the normalized-CI of the dead strain followed
the same tendency as the toxigenic control (Figure 4A).
Indeed, the statistical analysis performed at 4 and 22 h
after NCFS addition showed that live IPLA20022 had a
significantly (p < 0.05) higher normalized-CI, i.e., higher
protective capability, than the dead strain and the toxigenic
control (Figure 4A). Consequently, the immunohistochemistry
study confirmed that the morphology of HT29 treated for
20 h with the NCFS from dead B. longum IPLA20022 was
more similar to that obtained with the toxigenic control
(Figure 3). Indeed, besides the F-actin modification, some
apoptotic bodies were evidenced in both toxigenic and dead-
IPLA20022 samples (Supplementary Figure S2) suggesting that
the UV treatment of this strain, which probably affected the
structure and function of the cell envelope, abolished the anti-
clostridial effect of B. longum IPLA20022. Finally, we have
tested the activity against clostridial toxins of the supernatants
obtained from overnight cultures of this bifidobacterial strain.
Surprisingly, the normalized-CI values were similar to those
of those obtained with (live) pellets and both of them were
statistically (p < 0.05) higher than the toxigenic control
(Figure 4B). This result suggests that B. longum IPLA20022
is able to secrete factors having activity against the toxins of
C. difficile.
DISCUSSION
The search for novel approaches to treat or prevent CDI is a
current “hot-topic” in which the scientific community is devoting
much effort. Different approaches are under investigation, most
of them toward restoring the dysbiotic intestinal microbiota
following infection through FMT (Youngster et al., 2014;
Satokari et al., 2015) or using a consortia of defined species
(Lawley et al., 2012), but also toward the application of new
antibiotics (Babakhani et al., 2013; Vickers et al., 2015) and
drugs to treat infections (Oresic-Bender et al., 2015), as well
as vaccinations with non-toxigenic C. difficile strains (Senoh
et al., 2015) or anti-toxin antibodies (Yang et al., 2015). Probiotic
bacteriotherapy is becoming an option for the prevention of
C. difficile recurrent infection (Leﬄer and Lamont, 2015), and
also for the attenuation of CDI symptoms. The choice of the
appropriate probiotic against C. difficile is of pivotal relevance
since, although some formulations seem to be promising (Auclair
et al., 2015), not all of them are efficient (Allen et al.,
2013).
Probiotic action against CDI is based on different bacterial
antagonistic mechanisms, such as competition for adhesion
to gut mucosa (Banerjee et al., 2009; Zivkovic et al., 2015)
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FIGURE 3 | Immunofluorescence images obtained by CSLM of HT29 after 20 h of incubation without toxigenic C. difficile supernatant Tox-S (control)
and with Tox-S (damage control), and with NCFS (neutralized cell-free supernatants) obtained after incubation of live or dead B. longum IPLA20022
with Tox-S. (A) and (B) show a Z-projection (thickness about 13–15 µm) of 10 XY-slides and (C) shows a CSLM-zoom of a XY-region. (A) and (C) show the
combination of DAPI-stained nucleus (blue, excited at 405 nm by a blue–violet laser diode) and F-actin stained with Phalloidin-Alexa-Fluor-568 probe (red, excited at
578 nm by a white light laser); F-actin is also shown as a single channel in (B). Bars 10 µm.
and for colonization of the intestinal environment (Kondepudi
et al., 2014), production of antimicrobial molecules (Schoster
et al., 2013; Gebhart et al., 2015) or modulation of intestinal
inflammation (Boonma et al., 2014). Another target for probiotic
action is the reduction of toxicity caused by C. difficile (Trejo
et al., 2013). In any case, if one of the active strains would be
administered as a probiotic therapy to CDI patients, then the
effect would only be present as long as the probiotic is consumed
since stable colonization of probiotics in humans has not been
shown yet.
In our study, we have explored the capability of twenty
lactobacilli and bifidobacteria to counteract the effect of toxins
(TcdA and TcdB) from C. difficile LMG21717 (equivalent
to ATCC9689). The method used, based on impedance
Frontiers in Microbiology | www.frontiersin.org 8 April 2016 | Volume 7 | Article 577
fmicb-07-00577 April 20, 2016 Time: 13:59 # 9
Valdés-Varela et al. Probiotics against C. difficile Toxicity
FIGURE 4 | Evolution of the normalized cell index (CI) of HT29 monolayers treated with NCFS (neutralized cell-free supernatants) obtained after
incubation of toxigenic C. difficile supernatant (Tox-S) with live or dead B. longum IPLA20022 (A). Evolution of the normalized-CI of HT29 monolayers
treated with 2.5% of neutralized supernatant obtained after incubation of toxigenic C. difficile supernatant (Tox-S) with B. longum IPLA20022 supernatant (B).
Normalization was performed with respect to the point of NCFS’s addition and with respect to the control sample (culture medium MM without supernatant addition)
which is the 0-reference line (pink line). The dotted lines represent results obtained with the NCFS obtained after incubation of the live or dead B. longum IPLA20022
or culture supernatant in MM (without Tox-S). Histograms located in the right of (A) and (B) sections, represented the mean and standard deviation of normalized-CI
values obtained at 4 and 22 h from three biological replicates each measured in duplicate; within the same time, those means that do not share a common letter are
statistically different (p < 0.05) according to one-way ANOVA and the mean comparison SNK (Student-Newman–Keuls) test.
measurement of HT29 monolayers (Valdés et al., 2015),
allowed a quick search of the strains showing the highest
anti-toxin ability which those were belonging to B. longum
and B. breve species. This fact suggests that some species-
specific characteristics could account for the observed effect,
although differences were also detected among strains
within the same species. As far as we know, there are few
comparative studies among different probiotic species; Trejo
et al. (2010) co-cultivated two C. difficile strains (including
ATCC9689) with twenty five bifidobacteria or lactobacilli
and they found that the capability to antagonize the toxic
effect upon Vero line (monkey fibroblast-like kidney cells)
was strain dependent, but they did not report a species-
efficacy association. Nevertheless, the experimental procedure
used in our screening for detecting anti-toxicity was based
on the incubation of the probiotic strains with a toxigenic
supernatant from C. difficile, previous to analyze the effect
of NCFS upon the biological model HT29. Then, a priori,
the putative mechanisms that could be behind the anti-toxin
capability detected with our approach are the modification of the
C. difficile toxin and/or its availability for acting on the epithelial
cells.
Some authors have reported that probiotics are able to
reduce the activity of C. difficile toxins. Banerjee et al. (2009)
observed that Lactobacillus delbrueckii subsp. bulgaricus B-30892
releases bioactive components, of unknown nature, able to
decrease the toxic effect of C. difficile ATCC9689 upon epithelial
intestinal Caco2 cells. Similarly, Lactococcus lactis subsp. lactis
CIDCA8221 secretes heat-sensitive products, higher than 10 kDa,
that are not affected by treatment with proteases or protease-
inhibitors, which were able to protect Vero cells from C. difficile
toxins (Bolla et al., 2013). Saccharomyces boulardii releases an
extracellular serin-protease that was able to breakdown the
toxin A, as well as to inhibit its binding to the receptor in
the brush border of ileal tissue (Castagliuolo et al., 1996).
In our case, analysis of the bioactivity of the supernatant
collected from strain IPLA20022 directly incubated with the
toxigenic C. difficile supernatant showed similar effect on HT29
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than that obtained with the bifidobacterial pellet. Then, it seems
that this strain secreted molecules able to reduce the cytotoxic
effect of clostrial toxins. As far as we could find, no exo-proteases
have been described for bifidobacteria and only a few peptidases
have been characterized (Janer et al., 2005; Seo et al., 2007).
Additionally, other molecules inducing conformational changes
in proteins that disrupt the active site of other proteins, which
could putatively be involved in the inactivation of C. difficile
toxins, have been described; these are serpins (serin protein
inhibitors) found in the genome of B. longum (Schell et al., 2002)
and B. breve (Turroni et al., 2010) and ion chelating agents such
as the iron-chelating siderophores (Cronin et al., 2012; Vazquez-
Gutierrez et al., 2015). Thus, further and extensive work will
be needed in order to decipher the nature of the bifidobacterial
secreted factors acting against C. difficile toxicity.
Regarding the adsorption as mechanism to reduce toxins
activity, it has been demonstrated that the soluble S-layer protein
from the surface of L. kefir strains diminish the damage of
clostridial toxins upon Vero cells, suggesting a direct interaction
between the S-layer and the toxins (Carasi et al., 2012). However,
as far as we could know, this type of protein cover has not been
described for bifidobacteria. Additionally, cellular extracts from
L. acidophilus GP1B were able to interfere with quorum-sensing
signals from C. difficile and down-regulated expression of some
virulence genes; both, cellular extract and L. acidophilus strain,
were efficient in increasing the survival rate of animals in a CDI
murine model (Yun et al., 2014). The lactic acid synthesized by
this lactobacilli strain also had an inhibitory effect on C. difficile
growth. Similarly, Kolling et al. (2012) reported a bactericidal
effect induced by the lactic acid synthesized by Streptococcus
thermophilus LMD-9 and, furthermore, non-inhibitory levels
(10 mM) decreased the tcdA expression and toxin-A release. In
vivo (CDI mouse model) treatment with live S. thermophilus
showed a significant inverse correlation between levels of luminal
lactic acid and C. difficile abundance in the murine gut, thus
reducing the disease activity indexes of experimentation animals
(Kolling et al., 2012). In our experimental design, bifidobacteria
were in contact for 1 h only with the toxigenic clostridial
supernatant, but not with C. difficile, and the putative effect
of the organic acids (lactate and/or acetate) produced in this
short incubation period by lactobacilli or bifidobacteria was
neutralized.
Based on the results describe in this article, the adsorption
of toxins to the bifidobacterial surface as well as the presence
of secreted molecules responsible for the anti-toxigenic effect
observed, are both plausible mechanisms of action. Nevertheless
bacterial viability, which may be also needed to keep a
functional bifidobacterial envelope, is required in order to
maintain the anti-clostridial activity. Finally, the highest anti-
toxin capability of B. longum and B. breve strains (pointing
to a species-dependent efficacy) suggests that some specific
characteristics of these two phylogenetically close species (Lugli
et al., 2014) could account for the anti-clostridial toxicity.
Further experiments must be performed in order to understand
the mechanism of action behind bifidobacterial anti-C. difficile
toxicity. Another interesting observation that will deserve further
attention is the (apparently) better capability of B. bifidum,
and to a lower extent of B. breve, to specifically reduce TcdB
levels.
CONCLUSION
In this work we have optimized a protocol to search for potential
probiotics with anti-toxic activity against toxins synthesized by
C. difficile. The impedance-based, RTCA xCelligence was a fast,
reliable and efficient method for the screening of a large collection
of bacteria allowing the selection of those strains with higher
protection capability. In our case, strains from B. breve and
B. longum showed the better performance, since they were able to
reduce the levels of toxins from C. difficile supernatants. The best
candidate to be used as probiotic to alleviate CDI was B. longum
IPLA20022; this was the strain with the highest in vitro capability
for reducing the levels of clostrial toxins, as well as for avoiding
the cytopatic effect upon the intestinal epithelial cellular line
HT29. Apart for elucidating the mechanism behind this anti-
toxigenic capability, the next steps will be to study the efficacy
of B. longum IPLA20022 in more complex in vitro and in vivo
biological models before proposing its human application to
treat CDI.
AUTHOR CONTRIBUTIONS
MG and PR-M contributed with the conception, experimental
design and results interpretation of this study. LV-V carried
out all experiments, OG-S advised the immunohistochemistry
analysis and MA-G perform the CSLM analysis. PR-M was in
charge of writing the drafted manuscript. All authors performed a
critical revision of the manuscript and approved the final version.
ACKNOWLEDGMENTS
This work was fund by FEDER European Union funds through
the project AGL2012-33278 from the Spanish Ministry of
Economy and Competitiveness (MINECO), and through the
grants EQUIP11 and GRUPIN14-043 from the Program of
Science, Technology and Innovation from the “Principado de
Asturias”. LV-V acknowledges her JAE-Pre fellowship to CSIC.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2016.00577
FIGURE S1 | Final conditions used to perform the screening of the
anti-Clostridium difficile cytotoxic activity upon HT29 monolayers of
twenty bifidobacteria and lactobacilli strains (A). Scheme of the flow-work
followed to test the capability of Bifidobacterium longum IPLA20022 culture
supernatant to act against toxigenic C. difficile supernatant (B) MRSC, MRS broth
supplemented with 0.25% L-cysteine; MM, McCoy’s Medium added with
supplements and antibiotics described in material and methods section; NCFS,
neutralized cell-free supernatant.
Frontiers in Microbiology | www.frontiersin.org 10 April 2016 | Volume 7 | Article 577
fmicb-07-00577 April 20, 2016 Time: 13:59 # 11
Valdés-Varela et al. Probiotics against C. difficile Toxicity
FIGURE S2 | Immunofluorescence images obtained by CSLM of HT29 after
20 h of incubation without toxigenic C. difficile supernatant Tox-S (control)
and with Tox-S (damage control), and with NCFS (neutralized cell-free
supernatants) obtained after incubation of live or dead B. longum
IPLA20022 with Tox-S. Images show a CSLM-2.50 optical zoom of a XY-slide.
Upper-part images show the combination of DAPI-stained nucleus (blue, excite at
405 nm by a blue–violet laser diode) and F-actin stained with Phalloidin-Alexa
-Fluor-568 probe (red, excited at 578 nm by a white light laser) (A). Bottom-part
images show the same magnification view at the visible (transmitted light) channel
(B). Arrows indicates the apoptotic bodies. Bars 10 µm.
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